Last reviewed · How we verify
RP2 Monotherapy — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
RP2 Monotherapy (RP2 Monotherapy) — Replimune Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RP2 Monotherapy TARGET | RP2 Monotherapy | Replimune Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RP2 Monotherapy CI watch — RSS
- RP2 Monotherapy CI watch — Atom
- RP2 Monotherapy CI watch — JSON
- RP2 Monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). RP2 Monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/rp2-monotherapy. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab